Updated
Updated · GlobeNewswire · Jul 20
MRI Contrast Agents Market to Reach $2.17 Billion by 2030 as Chronic Disease Demand Lifts Growth
Updated
Updated · GlobeNewswire · Jul 20

MRI Contrast Agents Market to Reach $2.17 Billion by 2030 as Chronic Disease Demand Lifts Growth

2 articles · Updated · GlobeNewswire · Jul 20

Summary

  • $2.17 billion is the projected size of the global MRI contrast agents market by 2030, up from $1.64 billion in 2026 at a 7.4% annual growth rate.
  • Precision diagnostics, early disease detection and rising chronic disease burdens are driving that expansion, alongside broader hospital networks, outpatient imaging growth and continued MRI technology upgrades.
  • Product development is shifting toward safer and more targeted agents, including low-toxicity and nanoparticle-based options; Azurity's FDA-approved iron-based Ferabright launched in February 2026 for adult brain MRI.
  • North America was the largest market in 2025, while Asia-Pacific is expected to grow fastest through 2030 as healthcare investment, hospital capacity and MRI access expand.

Insights

What hidden challenges could hospitals and patients face as MRI contrast agents shift toward novel formulations and stricter environmental standards?
Could manganese-based MRI agents like GE's mangaciclanol truly replace gadolinium, or will safety and environmental concerns remain unsolved?